🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Czechia
Clinical trial register · European Union · CTIS

Clinical Trials in Czechia

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
44 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
2025-523826-41-00Dermatitis atopic
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase I
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
2025-521732-11-00No medical condition
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
12/02/2026
Phase I
The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 μg/mL Solution for Injection when administered sublingually in the dose of 500 μg and intramuscularly in the dose of 100 μg.
2025-524768-39-00Not applicable (submitted trial is a bioavalability study i…
Oxytone Bioscience B.V.
Female Urogenital Diseases and Pregnancy Complications
Czechia
09/02/2026
Phase I
Study to compare drug availability in the bloodstream of two oral formulations of dexketoprofen in healthy volunteers under fasting conditions.
2025-524061-24-01Bioequivalence clinical trial in healthy volunteers under f…
Faes Farma S.A.
Not possible to specify
Czechia
06/02/2026
Phase I
To evaluate the pharmacokinetics and safety of nolasiban
2025-523706-32-00not applicable (submitted trial is a pharmacokinetic study …
ReproNovo ApS
Female Urogenital Diseases and Pregnancy Complications
Czechia
09/01/2026
Phase I
Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)
2025-523010-89-00Pulmonary arterial hypertension
35Pharma Inc.
Cardiovascular Diseases
Hungary, Spain, Poland, Germany, Czechia
23/12/2025
Phase I
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fed conditions.
2025-524218-27-00treatment of myasthenia gravis
Vianex S.A.
Musculoskeletal Diseases
Czechia
19/12/2025
Phase I
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.
2025-524035-39-00Bioavailability study in healthy volunteers under fasting c…
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
09/12/2025
Phase I
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2025-524217-89-00treatment of myasthenia gravis
Vianex S.A.
Musculoskeletal Diseases
Czechia
01/12/2025
Phase I
A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment
2024-517923-38-00Newly diagnosed and/or previously treated IDH1-mutated mali…
Institut De Recherches Internationales Servier IRIS
Neoplasms
Czechia, Spain
24/11/2025
Phase I
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.
2025-523325-18-00Bioequivalence study under fasting conditions
Adamed Pharma S.A.
Mental Disorders
Czechia
13/10/2025
Phase I
Open-label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, study to assess the bioequivalence between the test product Betahistine dihydrochloride 24 mg tablets from Esperante Development BV and reference product Betaserc® 24 mg tablets.
2025-522971-27-00Bioequivalence study under fasting conditions
Esperante Development B.V.
Otorhinolaryngologic Diseases
Czechia
08/10/2025
Phase I
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
2025-522921-37-00inteneded for treatment of - active rheumatoid arthritis in…
Gebro Pharma GmbH
Skin and Connective Tissue Diseases
Czechia
11/09/2025
Phase I
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.
2025-522254-39-00Bioavailability study in healthy volunteers under fed condi…
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
10/09/2025
Phase I
Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.
2025-523137-25-00Comparative bioequivalence study in healthy volunteers unde…
MEDITOP Gyogyszeripari Kft.
Cardiovascular Diseases
Czechia
10/09/2025
Phase I
A randomised, open label, three periods, three-treatment crossover study to evaluate the pharmacokinetics of alendronic acid oral formulations after single dose administration in healthy volunteers under fasted conditions: a pilot study
2025-522606-20-00Pharmacokinetic study in healthy volunteers under fasted co…
Faes Farma S.A.
Musculoskeletal Diseases
Czechia
08/09/2025
Phase I
The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.
2025-522975-27-00Not applicable (submitted trial is a BE study in healthy su…
Adamed Pharma S.A.
Nutritional and Metabolic Diseases
Czechia
08/09/2025
Phase I
Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.
2025-523054-14-00not applicable (submitted trial is bioavailability)
Pharma Start LLC
Cardiovascular Diseases
Czechia
28/08/2025
Phase I
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.
2025-522562-70-00infection
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Bacterial Infections and Mycoses
Czechia
26/08/2025
Rows per page Showing 26–44 of 44
Previous 1 2
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/czechia

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.